Galiximab Biosimilar – Anti-CD80 mAb – Research Grade

Description of Galiximab Biosimilar - Anti-CD80 mAb - Research Grade

Introduction

Galiximab Biosimilar, also known as Anti-CD80 mAb, is a promising therapeutic antibody that has been developed as a biosimilar to the original drug galiximab. This monoclonal antibody targets the CD80 protein, which is a co-stimulatory molecule expressed on the surface of immune cells. In this article, we will explore the structure, activity, and potential applications of Galiximab Biosimilar in research.

Structure of Galiximab Biosimilar

Galiximab Biosimilar is a monoclonal antibody, meaning it is produced from a single clone of immune cells. It is a recombinant protein, meaning it is produced using genetic engineering techniques. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains are about 50 kDa each, while the light chains are about 25 kDa each. The antibody has a Y-shaped structure, with two identical antigen-binding sites at the ends of the Y arms.

Activity of Galiximab Biosimilar

Galiximab Biosimilar specifically targets the CD80 protein, which is a co-stimulatory molecule expressed on the surface of antigen-presenting cells (APCs). This protein plays a crucial role in the activation of T cells, a type of immune cell that is responsible for fighting off pathogens and cancer cells. By binding to CD80, Galiximab Biosimilar blocks the interaction between CD80 and its receptor on T cells, thus inhibiting T cell activation. This leads to a decrease in the production of pro-inflammatory cytokines and a reduction in the proliferation of T cells.

Applications of Galiximab Biosimilar

Galiximab Biosimilar has potential applications in various areas of research, including immunology, oncology, and transplantation. In immunology, it can be used to study the role of CD80 in T cell activation and the development of autoimmune diseases. In oncology, Galiximab Biosimilar can be used to target CD80-expressing cancer cells, particularly in hematological malignancies such as B-cell lymphomas. It has also shown promising results in combination with other anti- cancer drugs, such as rituximab, in the treatment of non-Hodgkin’s lymphoma. In transplantation, Galiximab Biosimilar can be used to prevent graft rejection by inhibiting T cell activation.

Advantages of Galiximab Biosimilar

As a biosimilar, Galiximab Biosimilar offers several advantages over the original drug, including lower cost, increased accessibility, and potentially improved efficacy. Biosimilars are produced using the same manufacturing process as the original drug, ensuring a high level of similarity in structure and activity. This also means that they have a comparable safety profile to the original drug. Additionally, biosimilars have the potential to increase competition in the market, leading to lower prices and increased accessibility for patients.

Conclusion

In summary, Galiximab Biosimilar is a promising therapeutic antibody that specifically targets the CD80 protein. Its structure, activity, and potential applications make it a valuable tool in research, particularly in the fields of immunology, oncology, and transplantation. As a biosimilar, it offers several advantages over the original drug, making it a cost-effective and accessible option for researchers. Further studies and clinical trials are needed to fully explore the potential of Galiximab Biosimilar and its role in the treatment of various diseases.

SDS-PAGE for Galiximab Biosimilar - Anti-CD80 mAb

Galiximab Biosimilar - Anti-CD80 mAb, on SDS-PAGE under reducing and non-reducing conditions. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.